Familial Cancer

, Volume 5, Issue 2, pp 129–133

Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management

Article

Key words

breast cancer correlation damage genotype implications Li Fraumeni syndrome phenotype prevention screening TP53 treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Li, FP, Fraumeni, JF,Jr., Mulvihill, JJ, Blattner, WA, Dreyfus, MG, Tucker, MA,  et al. 1988A cancer family syndrome in twenty-four kindredsCancer Res48535862PubMedGoogle Scholar
  2. 2.
    Kleihues, P, Schauble, B, zur, HA,  et al. 1997Tumors associated with p53 germline mutations: A synopsis of 91 familiesAm J Pathol150113PubMedGoogle Scholar
  3. 3.
    Olivier, M, Goldgar, DE, Sodha, N,  et al. 2003Li-Fraumeni and related syndromes: Correlation between tumour type, family structure, and TP53 genotypeCancer Res63664350PubMedGoogle Scholar
  4. 4.
    Bell, DW, Varley, JM, Szydlo, TE, Kang, DH, Wahrer, DC, Shannon, KE,  et al. 1999Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndromeScience286252831PubMedCrossRefGoogle Scholar
  5. 5.
    Sodha, N, Houlston, RS, Bullock, S, Yuille, MA, Chu, C, Turner, G,  et al. 2002Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndromeHum Mutat204602PubMedCrossRefGoogle Scholar
  6. 6.
    Yoon, H, Liyanarachchi, S, Wright, F. A, Liyanarachchi, S, Davuluri, R, Lockman, J. C, Chapelle, A,  et al. 2002Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53Proc Nat Acad Sci9156327CrossRefGoogle Scholar
  7. 7.
    Chompret, A, Brugieres, L, Ronsin, M,  et al. 2000P53 germline mutations in childhood cancers and cancer risk for carrier individualsBr J Cancer8219327PubMedCrossRefGoogle Scholar
  8. 8.
    Ribeiro, RC, Sandrini, F, Figueiredo, B, Zambetti, GP, Micahlkiewicz, E, Lafferty, AR,  et al. 2001An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinomaProc Natl Acad Sci USA9893305PubMedCrossRefGoogle Scholar
  9. 9.
    Plummer, SJ, Santibanez-Koref, M, Kurosaki, T,  et al. 1994A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome familyOncogene9327380PubMedGoogle Scholar
  10. 10.
    Varley, JM, McGown, G, Thorncroft, M,  et al. 1996A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndromeOncogene12243742PubMedGoogle Scholar
  11. 11.
    Lomax, ME, Barnes, DM, Gilchrist, R,  et al. 1997Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like familyOncogene14186974PubMedCrossRefGoogle Scholar
  12. 12.
    Davison, TS, Yin, P, Nie, E,  et al. 1998Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndromeOncogene176516PubMedCrossRefGoogle Scholar
  13. 13.
    May, P, May, E 1999Twenty years of p53 research: structural and functional aspects of the p53 proteinOncogene18762136PubMedCrossRefGoogle Scholar
  14. 14.
    Varley, JM, Thorncroft, M, McGown, G,  et al. 1997A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 geneOncogene1486571PubMedCrossRefGoogle Scholar
  15. 15.
    Birch, JM, Blair, V, Kelsey, AM, Evans, DG, Harris, M, Tricker, KJ,  et al. 1998Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndromeOncogene1710618PubMedCrossRefGoogle Scholar
  16. 16.
    Dittmer, D, Pati, S, Zambetti, G, Chu, S, Teresky, AK, Moore, M,  et al. 1993Gain of function mutations in p53Nat Genet4426PubMedCrossRefGoogle Scholar
  17. 17.
    Sidransky, D, Tokino, T, Helzlsouer, K, Zehnbauer, B, Rausch, G, Shelton, B,  et al. 1992Inherited p53 gene mutations in breast cancerCancer Res5229846PubMedGoogle Scholar
  18. 18.
    Lane, DP, Crawford, LV 1979T antigen is bound to a host protein in SV40-transformed cellsNature2782613PubMedCrossRefGoogle Scholar
  19. 19.
    Little, JB 2003Genomic instability and bystander effects: A historical perspectiveOncogene22697887PubMedCrossRefGoogle Scholar
  20. 20.
    Liang, L, Shao, C, Deng, L, Mendonca, MS, Stambrook, PJ, Tischfield, JA,  et al. 2002Radiation-induced genetic instability in vivo depends on p53 statusMutat Res5026980PubMedGoogle Scholar
  21. 21.
    Suzuki, K, Ojima, M, Kodama, S, Watanabe, M 2003Radiation-induced DNA damage and delayed induced genomic instabilityOncogene22698893PubMedCrossRefGoogle Scholar
  22. 22.
    Shay, JW, Tomlinson, G, Piatyszek, MA, Gollahon, LS 1995Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndromeMol Cell Biol1542532PubMedGoogle Scholar
  23. 23.
    Tsutsui, T, Fujino, T, Kodama, S, Tainsky, MA, J, Boyd, Barrett, JC,  et al. 1995Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndromeCarcinogenesis162534PubMedGoogle Scholar
  24. 24.
    Varley, JM, Evans, DG, Birch, JM 1997Li-Fraumeni syndrome–a molecular and clinical reviewBr J Cancer76114PubMedGoogle Scholar
  25. 25.
    Liu, PK, Kraus, E, Wu, TA,  et al. 1996Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutationsOncogene12226778PubMedGoogle Scholar
  26. 26.
    Delia, D, Goi, K, Mizutani, S, Yamada, T, Aiello, A, Fontnella, E,  et al. 1997Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutationsOncogene14213747PubMedCrossRefGoogle Scholar
  27. 27.
    Lowe, SW, Bodis, S, McClatchey, A,  et al. 1994p53 status and the efficacy of cancer therapy in vivoScience26680710PubMedGoogle Scholar
  28. 28.
    Lowe, SW, Ruley, HE, Jacks, T, Housman, DE 1993p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell7495767PubMedCrossRefGoogle Scholar
  29. 29.
    Heyn, R, Haeberlen, V, Newton, WA,  et al. 1993Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study CommitteeJ Clin Oncol1126270PubMedGoogle Scholar
  30. 30.
    Hisada, M, Garber, JE, Fung, CY,  et al. 1998Multiple primary cancers in families with Li-Fraumeni syndromeJ Natl Cancer Inst9060611PubMedCrossRefGoogle Scholar
  31. 31.
    Limacher, JM, Frebourg, T, Natarajan-Ame, S, Bergerat, JP 2001Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndromeInt J Cancer9623842PubMedCrossRefGoogle Scholar
  32. 32.
    Nutting, C, Camplejohn, RS, Gilchrist, R,  et al. 2000A patient with 17 primary tumours and a germ line mutation in TP53: Tumour induction by adjuvant therapy?Clin Oncol (R Coll Radiol)23004Google Scholar
  33. 33.
    Tabar, L, Fagerberg, CJ, Gad, A,  et al. 1985Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and WelfareLancet182932PubMedCrossRefGoogle Scholar
  34. 34.
    Tabar, L, Fagerberg, G, Chen, HH,  et al. 1995Efficacy of breast cancer screening by age. New results from the Swedish Two-County TrialCancer75250717PubMedGoogle Scholar
  35. 35.
    Breast-cancer screening with mammography in women aged 40–49 years. Swedish Cancer Society and the Swedish National Board of Health and Welfare. Int J Cancer 1996; 68(6): 693–699Google Scholar
  36. 36.
    Law, J 1997Cancers detected and induced in mammographic screening: new screening schedules and younger women with family historyBr J Radiol70629PubMedGoogle Scholar
  37. 37.
    Warner, E, Plewes, DB, Shumak, RS,  et al. 2001Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancerJ Clin Oncol19352431PubMedGoogle Scholar
  38. 38.
    Leach, MO, Boggis, CR, Dixon, AK,,  et al. 2005Screening with magnetic resonance imaging and mammograpy of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)Lancet365176978PubMedCrossRefGoogle Scholar
  39. 39.
    Liu, MC, Gelmann, EP 2002P53 gene mutations: Case study of a clinical marker for solid tumorsSemin Oncol2924657PubMedCrossRefGoogle Scholar
  40. 40.
    Narod, SA, Brunet, JS, Ghadirian, P,  et al. 2000Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case–control study. Hereditary Breast Cancer Clinical Study GroupLancet356187681PubMedCrossRefGoogle Scholar
  41. 41.
    Hursting, SD, Perkins, SN, Haines, DC,  et al. 1995Chemoprevention of spontaneous tumorigenesis in p53-knockout miceCancer Res55394953PubMedGoogle Scholar
  42. 42.
    Fisher, B, Costantino, JP, Wickerham, DL,  et al. 1998Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst90137188PubMedCrossRefGoogle Scholar
  43. 43.
    Evans, DG, Lalloo, F 2002Risk assessment and management of high risk familial breast cancerJ Med Genet3986571PubMedCrossRefGoogle Scholar
  44. 44.
    Rebbeck, TR, Friebel, T, Lynch, HT,  et al. 2004Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study GroupJ Clin Oncol22105562PubMedCrossRefGoogle Scholar
  45. 45.
    Hopwood, P, Lee, A, Shenton, A,  et al. 2000Clinical follow-up after bilateral risk reducing (ȁ8prophylactic’) mastectomy: Mental health and body image outcomesPsychooncology946272PubMedCrossRefGoogle Scholar
  46. 46.
    Van, OI, Meijers-Heijboer, H, Lodder, LN,  et al. 2003Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up studyJ Clin Oncol21386774CrossRefGoogle Scholar
  47. 47.
    Snyder, EL, Meade, BR, Saenz, CC, Dowdy, SF 2004Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptidePLoS Biol2E36PubMedCrossRefGoogle Scholar
  48. 48.
    Lane, D 2004Curing cancer with p53N Engl J Med35027112PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  1. 1.Cancer Genetics Unit and Academic Unit of RadiotherapyRoyal Marsden NHS Foundation TrustLondonUK
  2. 2.Meyerstein Institute of OncologyMiddlesex HospitalLondonUK
  3. 3.Sections of Cancer Genetics and Molecular CarcinogenesisInstitute of Cancer ResearchSutton SurreyUK
  4. 4.Section of Cancer GeneticsInstitute of Cancer ResearchSutton SurreyUK

Personalised recommendations